News
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
A key vaccine advisory committee is meeting for the first time under new U.S. Health Secretary Robert F. Kennedy Jr., a ...
Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug ...
The price of pharmaceuticals will likely go up soon, and generics are poised to be hit the hardest.
The wide-ranging executive order signed by Trump aims to reduce healthcare costs. It comes one day after the Trump ...
Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...
14h
Irish Star on MSNMegyn Kelly gives health update as she rages over vaccine side effect claimMegyn Kelly talks about how her vaccine shots and follow-up booster is the cause of an "autoimmune condition" that she ...
Pfizer decided to abort the clinical trial of its daily weight loss pill 'Danuglipron' after one patient in a trial showed signs of liver damage, likely to be caused by the drug.
PARIS (Reuters) -Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, ...
Its statement also suggested the patient’s liver enzymes were elevated. That often is indicative of damage to cells in the organ, according to the Cleveland Clinic. Pfizer told CNBC that the trial ...
Pfizer Inc. (PFE) is currently at $22.83, up $0.71 or 3.19% --Would be highest close since April 4, 2025, when it closed at $22.97 --On pace for largest percent increase since Dec. 17, 2024, when it ...
Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results